Repurposing Off-Patent Drugs Derisks Safety Hurdles for Rare Diseases
Jennifer Lynn · We Interviewed the New Thiel Fellow Dropouts · May 28, 2025 · at 1:18:11
Jennifer Lynn, founder of AUG and Thiel Fellow, discusses her company's strategy of reformulating established molecules for rare diseases.
0:00 / 0:10exact quote · 10.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Repurposing old drugs is a great strategy because you have safety usually already established for patients. Now you just have to work on making sure that it's like a drug that works.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jennifer Lynn
New FDA Guidance Reduces Animal Testing Requirements for Antibody Biologics
“So they just recently released the guidance that certain biologic drugs, antibodies don't have to go after as much animal testing. You can leverage a lot of human clinical trials, which is like almost incorporating common sense, right?”